NEW YORK (GenomeWeb News) – Siena Biotech has retained Proteome Sciences under a Master Research Agreement to supply protein and peptide biomarkers services for its drug discovery programs, Proteome announced today.
The UK-based proteomics firm added that as the first project under the agreement it will apply its PS Biomarkers services to analyze post-translational modifications on a neurological disease-related protein. Using its sample preparation and analytical methods in combination with Thermo Fisher Scientific's Orbitrap Velos mass spectrometry, Proteome will "deliver a high-density PTM map of Siena Biotech's protein target."
Such maps can confirm proof of disease mechanism and/or mode of action of targeted therapeutics to help a drug firm decide whether to proceed with further development, Proteome said.
Financial and other terms of the deal were not disclosed.
Siena Biotech is a clinical-stage drug development firm based in Italy.